Head of Investor Relations - Deborah Elson Executive Vice President of Commercial Operations - Thomas Englese Chief Financial Officer - Bradley Saenger Operator: Good morning, and welcome to the Tonix Pharmaceuticals Second Quarter 2026 Financial Results and Business Update Conference Call. [Operator Instructions] As a reminder, this call is being recorded. I would now like to turn the call over to Deborah Elson, Head of Investor Relations at Tonix Pharmaceuticals. Deborah Elson: Thank you, Operator, and good morning, everyone.
We appreciate you joining us today to discuss Tonix Pharmaceuticals' second quarter 2026 financial results and operational highlights. Before we begin, I would like to remind everyone of the disclaimers on Slide 2 that any statements made on today's call that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
These risks are described more fully in our filing with the Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2025, and our subsequent periodic reports. Tonix undertakes no obligation to update or revise any forward statements, except as required by law. Joining me on today's call are Dr.
Seth Lederman, Chief Executive Officer; Thomas Englese, Executive Vice President of Commercial Operations; and Bradley Saenger, Chief Financial Officer. With that, I will turn the call over to Seth. Seth Lederman: Thank you, Deborah, and good morning, everyone.
We're pleased to welcome you to Tonix's earnings call. Today we're reporting second quarter financial results and operational highlights that reflect strong execution in both our commercial business and advancing our development pipeline. We are focused on improving the care for patients with debilitating conditions or preventing illness before it happens.
We believe each of the commercial products and the development candidates target major unmet medical needs. As you can see on Slide 2, the launch of TONMYA is progressing well, supported by growing sales, improvement across launch metrics, and patient access wins. TONMYA was invented, developed, tested, and launched in-house by the Tonix team.
Extract — continue reading at the source.
